Crossmark

If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis

Crossref DOI link: https://doi.org/10.1007/s11606-018-4498-3

Published Online: 2018-06-04

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Deloughery, Emma P.

Prasad, Vinay
License Information

Text and Data Mining valid from 2018-06-04
More Information

Article History

Received: 26 March 2018

Revised: 16 May 2018

Accepted: 16 May 2018

First Online: 4 June 2018

Compliance with Ethical Standards

:

: Dr Prasad is the author of Ending Medical Reversal, and receives royalties.

Document is current

Any future updates will be listed below